2018-06-09 16:40:00 Sat ET
technology antitrust competition bilateral trade free trade fair trade trade agreement trade surplus trade deficit multilateralism neoliberalism world trade organization regulation public utility current account compliance
The Trump administration introduces new tariffs on $50 billion Chinese goods amid the persistent bilateral trade dispute. The tariffs effectively boost costs and prices for American consumers and enterprises. The delivery company FedEx views U.S. tariffs on Chinese goods as *counterproductive to U.S. economic interests*. China counteracts these penalties by imposing 25% retaliatory tariffs on $50 billion U.S. farm imports such as beef, cotton, rice, soy, and wheat. This recent Sino-U.S. trade conflict may herald a new era of much greater trade protectionism.
The U.S. major stock indices S&P 500, Dow, and NASDAQ experience discernible losses in response to the core complex trifecta of Sino-U.S. trade tension, Federal Reserve second interest rate hike, and energy cost momentum. In addition to this negative U.S. stock market return performance, the greenback exhibits much more volatile near-term gyrations in the foreign exchange market. In a putative trade war, there are winners and losers; whereas, everyone suffers in a major trade conflict. Full-scale and all-out tit-for-tat would become a suboptimal approach to resolving the current bilateral trade imbalance.
It is important for each side to refrain from undertaking any unilateral actions to complicate the status quo. Both sides need to consider a better balance between carrots and sticks in addressing the Sino-U.S. trade dilemma.
If any of our AYA Analytica financial health memos (FHM), blog posts, ebooks, newsletters, and notifications etc, or any other form of online content curation, involves potential copyright concerns, please feel free to contact us at service@ayafintech.network so that we can remove relevant content in response to any such request within a reasonable time frame.
2018-09-01 07:34:00 Saturday ET
As the French economist who studies global economic inequality in his recent book *Capital in the New Century*, Thomas Piketty co-authors with John Bates Cl
2018-01-23 06:38:00 Tuesday ET
Amazon, Berkshire Hathaway, and JPMorgan Chase establish a new company to reduce U.S. employee health care costs in negotiations with drugmakers, doctors, a
2019-06-07 04:02:05 Friday ET
The world seeks to reduce medicine prices and other health care costs to better regulate big pharma. Nowadays the Trump administration requires pharmaceutic
2022-10-05 08:24:00 Wednesday ET
Precautionary-motive and agency reasons for corporate cash management Bates, Kahle, and Stulz (JF 2009) empirically find that public firms have doubled t
2024-05-05 10:31:00 Sunday ET
Stock Synopsis: Pharmaceutical post-pandemic patent development cycle In terms of stock market valuation, the major pharmaceutical sector remains at its
2020-01-01 13:39:00 Wednesday ET
President Trump approves a phase one trade agreement with China. This approval averts the introduction of new tariffs on Chinese imports. In return, China s